Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

Overview of attention for article published in Nature Cancer, April 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

blogs: 1 blog
twitter: 11 X users

guideline: 1 clinical guideline source
bluesky: 2 Bluesky users

Readers on

mendeley: 36 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 482 followers.

Very important study offering therapeutic option for DLBCL patients failing CD19-CAR-T cell therapy. www.nature.com/articles/s43...

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.